Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 689

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 689
---
) R& D: comprises research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administr...
(b) Marketed Products: comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities including out-licensed marketed products.
(ii) Other Ventures: comprises other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
In general, revenue, cost of revenue and operating expenses are directly attributable, or are allocated, to each segment. The Company allocates costs and expenses that are not directly attributable to a specific segment mainly on the basis of headcount or usage, depending on the nature of the relevant costs and expenses. The Company does not allocate assets to its segments as the CODM does not evaluate the performance of segments using asset information.
The performance of the reportable segments is assessed based on segment net income/(loss) attributable to the Company.

F-50

Table of Contents

(i)Segment information:
Year Ended December 31, 2024
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Oncology/Immunology
Marketed Other
R& D Products Subtotal Ventures Unallocated Total
(in US$ ’ 000)
Revenue from external customers 91,831 271,534 363,365 266,836 - 630,201
Cost of revenue - ( 92,783) ( 92,783) ( 256,101) - ( 348,884)
Research and development expenses ( 212,109) - ( 212,109) - - ( 212,109)
Selling expenses - ( 44,287) ( 44,287) ( 4,330) - ( 48,617)
Administrative expenses ( 36,126) ( 784) ( 36,910) ( 4,996) ( 22,390) ( 64,296)
Interest income 818 - 818 182 39,080 40,080
Interest expense ( 1,825) - ( 1,825) ( 653) ( 394) ( 2,872)
Equity in earnings of an equity investee, net of tax - - - 46,469 - 46,469
Income tax (expense)/benefit ( 3,475